HC Wainwright Predicts Lower Earnings for BioLife Solutions

BioLife Solutions, Inc. (NASDAQ:BLFS) – Analysts at HC Wainwright lowered their Q3 2025 earnings estimates for shares of BioLife Solutions in a report released on Tuesday, May 27th. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will post earnings per share of ($0.04) for the quarter, down from their prior forecast of ($0.02). HC Wainwright currently has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.02 EPS and Q4 2026 earnings at $0.04 EPS.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million for the quarter, compared to analyst estimates of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%.

Separately, Wall Street Zen lowered shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.17.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $22.32 on Thursday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -21.06 and a beta of 2.01. The firm’s fifty day simple moving average is $22.94 and its 200 day simple moving average is $25.09. BioLife Solutions has a twelve month low of $18.70 and a twelve month high of $29.55.

Insider Buying and Selling

In other news, CMO Todd Berard sold 1,577 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now owns 104,961 shares of the company’s stock, valued at approximately $2,624,025. The trade was a 1.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Troy Wichterman sold 4,151 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $103,775.00. Following the completion of the sale, the chief financial officer now directly owns 116,809 shares of the company’s stock, valued at $2,920,225. The trade was a 3.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,696 shares of company stock valued at $1,665,094 in the last quarter. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently modified their holdings of BLFS. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions in the 4th quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the 4th quarter valued at about $31,000. State of Wyoming grew its position in shares of BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 1,490 shares during the last quarter. US Bancorp DE grew its position in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 1,528 shares during the last quarter. Finally, 1620 Investment Advisors Inc. grew its position in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 675 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.